The New England Bladder Cancer Study
NCT00342875 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2681
Last updated 2020-07-15
Summary
Data from the new cancer atlas covering the period 1974 1994 indicates that deaths from bladder cancer among white men and women are elevated in the northeastern United States, particularly the northern parts of New England. The reason for these elevated rates of incidence of and deaths from bladder cancer is unknown. Only part of the excess risk can be explained by exposure to the textile and leather industries.
The purpose of this study is to determine the factors that contribute to the high rates of incidence of and death from bladder cancer in northern New England. The main objectives are to:
* estimate the risk of developing bladder cancer associated with inorganic arsenic in drinking water, other water contaminants, tobacco use, occupational exposures, residential proximity to industrial sites, dietary factors, ethnicity, and use of wood-burning stoves.
* estimate the extent to which water containing inorganic arsenic explains the increased rates of bladder cancer.
* estimate the extent to which exposure to other risk factors explains the increased rates.
* evaluate risk of bladder cancer according to genetic factors.
* examine interactions of these factors with tobacco use, occupational exposure, and environmental exposure to arsenic and other compounds.
All people ages 30 79 with confirmed cases of bladder cancer will be eligible for the study. Twelve hundred people with bladder cancer and twelve hundred individuals with no previous bladder cancer will be included.
After potential participants are recruited and agreement is obtained over the telephone, they will complete a calendar and collect toenail clippings prior to the home interview. During the home visit, an investigator will administer a computer-assisted personal interview, collect drinking water samples and the clippings, and obtain a global positioning satellite reading. Other biological samples, such as saliva samples, urine, and blood, may be requested.
Private wells at any previous homes of participants will also be sampled. The location of previous homes will be determined and the current homeowner will be asked to allow sampling of the well.
The associations between bladder cancer and environmental exposures will be examined and the extent to which exposures to such risk factors explain the elevated mortality and incidence in northern New England will be estimated.
...
Conditions
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Debra Silverman, D.Sc. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 30 Years
- Max Age
- 79 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-03-01
- Primary Completion
- 2004-06-16
- Completion
- 2020-07-14
Countries
- United States
Study Locations
More Related Trials
-
Prognostic Biomarkers in Patients With Urothelial Carcinoma
NCT04872036 ·Status: COMPLETED
-
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
NCT02700464 ·Status: COMPLETED ·Phase: NA
-
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429 ·Status: RECRUITING
-
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
NCT03413982 ·Status: RECRUITING
-
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
NCT02647112 ·Status: COMPLETED ·Phase: NA
-
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
NCT06412874 ·Status: COMPLETED
-
Cost-Effectiveness in Bladder Cancer
NCT00126958 ·Status: UNKNOWN
-
Assessment of BladderLight SurvEILlance
NCT03427034 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
An Educational Intervention for Patients With Bladder Cancer
NCT01915121 ·Status: COMPLETED ·Phase: NA
-
To Detect the Sensitivity of the UroMark Assay
NCT02781428 ·Status: COMPLETED
-
Personalized Urine Biomarker for Patients With Bladder Cancer
NCT05467267 ·Status: UNKNOWN
-
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
NCT06870253 ·Status: ACTIVE_NOT_RECRUITING
-
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
NCT03892642 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
MK-3475/BCG in High Risk Superficial Bladder Cancer
NCT02324582 ·Status: COMPLETED ·Phase: PHASE1
-
Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma
NCT00867620 ·Status: UNKNOWN
-
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
NCT07225127 ·Status: RECRUITING
-
Interdisciplinary Case-Control Study of Bladder Cancer in Spain
NCT00341861 ·Status: COMPLETED
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504 ·Status: RECRUITING
-
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301 ·Status: COMPLETED
-
Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different Methods
NCT00339443 ·Status: COMPLETED
-
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
NCT02808143 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
NCT03375307 ·Status: SUSPENDED ·Phase: PHASE2
-
Bladder Cancer Screening Trial
NCT05646485 ·Status: RECRUITING ·Phase: NA
-
A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer
NCT03854721 ·Status: COMPLETED ·Phase: PHASE1